Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases

Gynecologic Oncology

Volumn 89, Issue 1, 2003, Pages 9-15

  Concin, Nicole ^a   Hefler, Lukas ^b   Van Bavel, Jeroen ^c   Mueller Holzner, Elisabeth ^a   Zeimet, Alain ^a   Daxenbichler, Guenter ^a   Speiser, Paul ^a   Hacker, Neville ^d   Marth, Christian ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

CD44s; CD44v6; HER2 neu; Ki 67; Lymph node metastases; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; HERMES ANTIGEN; KI 67 ANTIGEN; ONCOPROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OMENTECTOMY; OVARY CANCER; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SALPINGOOOPHORECTOMY; SURGICAL TECHNIQUE;

EID: 0345701471     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(02)00147-6     Document Type: Article

References (34)

1. Bergman F. Carcinoma of the ovary a clinco-pathological study of 86 autopsied cases with special reference to mode of spread . Acta Obstet Gynecol Scand. 45:1966;211-231.
2. Gynecol Oncol. 25:1986;383.
3. Di Re F., Fontanelli R., Raspagliesi F., di Re E. Pelvic and para-aortic lymphadenectomy in cancer of the ovary. Burghardt E., Monaghan J.M. Clinical obstetrics and gynecolog. Vol 2:1989;131-142 BalliereTindall, London.
4. Burghardt E., Girardi F., Lahousen M., Tamussino K., Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 40:1991;103-106.
5. Benedetti-Panici P., Greggi S., Maneschi F., Scambia G., Amoroso M., Rabitti C., Mancuso S. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol. 51:1993;150-154.
6. Petru E., Lahousen M., Tamussino K., Pickel H., Stranzl H., Stettner H., Winter R. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol. 170(2):1994;656-662.
7. Baiocchi G., Raspagliesi F., Grosso G. Early ovarian cancer. Is there a role for systematic pelvic and para-aortic lymphadenectomy? Int J Gynecol Oncol. 8:1998;103-108.
8. Sakuragi N., Yamada H., Oikawa M., Okuyama K., Fujino T., Sagawa T., Fujimott S. Prognostic significance of lymph node metastasis and clear cell histology in 79:2 ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). Gynecol Oncol. 79:2000;251-255.
9. Suzuki M., Ohwada M., Yamada T., Kohon T., Sekiguchi I., Sato I. Lymph node metastasis in stage I ovarian cancer. Gynecol Oncol. 79:2000;305-308.
10. De Poncheville L., Perrotin F., Lefrancq T., Lansac J., Body G. Does paraaortic lymphadenectomy have a benefit in the treatment of ovarian cancer that is apparently confined to the ovaries? Eur J Cancer. 37:2001;210-215.
11. Di Re F., Baiocchi G. Value of lymph node assessment in ovarian cancer status of the art at the end of the second millennium . Int J Gynecol Cancer. 10:2000;435-442.
12. Soper J.T., Johnson P., Johnson V., Berchuck A., Clarke-Pearson D.L. Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol. 80:(6):1992;949-953.
13. Young R., Walton L., Ellenberg S., Homesley H., Wilbanks G., Decker D. Adjuvant therapy in stage I and II epithelial ovarian cancer. N Engl J Med. 15:1990;1021-1027.
14. Seidman J.D., Russell P., Kurman R.J. Surface epithelial tumors of the ovary. Kurman R.J. Blausein's pathology of the female genital tract. 5th ed:2002;808-887 Springer Verlag, New York/Berlin/Heidelberg.
15. Anttila M., Kosma V.M., Ji H., Wei-Ling X., Puolakka J., Johola M., Saarikoski S., Syrjänen K. Clinical significance of α-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. JCO. 8:(16):1998;2591-2699.
16. Speiser P., Wanner C., Tempfer C., Mittelböck M., Hanzal E., Bancher-Todesca D., Gitsch G., Reinthaller A., Kainz C. CD44 is an independent prognostic factor in early-stage cervical cancer. Int J Cancer. 74:1997;185-188.
17. Schneider J., Pollan M., Ruibal A., Jimenez E., Lucas A.R., Nunez M.I., Sanchez J., Tejerina A. Histological grade and CD44 are independent predictors of axillary lymph node invasion in early (T1) breast cancer. Tumor Biol. 20:(6):1999;319-330.
18. Riou G, Mathieu MC, Barrois M, Le Bihan ML, Ahomadegbe JC, Benard J, Le MG. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer 2001; 20;95(4):266-70.
19. Matsumoto M., Komiyama K., Okaue M., Shimoyama Y., Iwakami K., Namaki S., Tanaka H., Mono I., Sato H. Predicting tumor metastasis in patients with oral cancer by means of the proliferation marker Ki67. J Oral Sci. 41:(2):1999;53-56.
20. Schneider J., Gonzalez-Roces S., Pollan M., Lucas R., Tejerina A., Martin M., Alba A. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res. 3:(3):2001;183-191.
21. Underhill C. CD44 the hyaluronan receptor . J Cell Sci. 103:1992;293-298.
22. Speiser P., Wanner C., Breitenecker G., Kohlberger P., Kainz C. CD-44 is not involved in the metastatic spread of ovarian cancer in vivo. Anticancer Res. 15:1995;2767-2769.
23. Yorishima T., Nagai N., Ohama K. Expression of CD44 alternative splicing variants in primary and lymph node metastatic lesions of gynecological cancer. Hiroshima J Med Sci. 46:(1):1997;21-29.
24. Yamada Y., Yoshimoto M., Murayama Y., Ebuchi M., Mori S., Yamamoto T., Sugano H., Toyoshima K. Association of elevated expression of the c-erB-2 protein with spread of breast cancer. Jpn J Cancer Res. 80:(12):1989;1192-1198.
25. Orita H., Maehara Y., Emi Y., Kakeji Y., Baba H., Korenaga D., Sugimachi K. c-erB-2 expression in predictive for lymphatic spread of clinical gastric carcinoma. Hepatogastroenterology. 44:(13):1997;294-298.
26. Wong Y.F., Cheung T.H., Lam S.K., Lu H.J., Zhuang Y.L., Chan M.Y., Chung T.K. Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. Gynecol Obstet Invest. 40:(3):1995;209-212.
27. Afify A.M., Werness B.A., Mark H.F. HER-2/neu oncogene amplification in stage I and stage II ovarian papillary serous carcinoma. Exp Mol Pathol. 66:(2):1999;163-169.
28. Fukushi Y., Sato S., Yokoyama Y., Kudo K., Maruyama H., Saito Y. Detection of numerical aberration in chromsome 17 and c-erbB2 gene amlification in epithelial ovarian cancer using recently established dual color FISH. Eur J Gynaecol Oncol. 22:(1):2001;23-25.
29. Vergote I., De Brabanter J., Fyles A., Bertelsen K., Einhorn N., Sevelda P., Gore M.E., Kaern J., Verrelst H., Sjovall K., Timmerman D., Vandewalle J., Van Gramberen M., Trope C.G. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 357:(9251):2001;176-182.
30. Valverde J.J., Martin M., Garcia-Asenjo J.A., Casado A., Vidart J.A., Diaz-Rubio E. Prognostic value of DNA quantification in early epithelial ovarian carcinoma. Obstet Gynecol. 97:(3):2001;409-416.
31. Skimisdottir I., Sorbe B., Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer. 11:(2):2001;119-129.
32. Uhl-Steidl M., Muller-Holzner E., Zeimet A.G., Adolf G.R., Daxenbichler G., Marth C., Dapunt O. Prognostic value of CD44 splice variant expression in ovarian cancer. Oncology. 52:(5):1995;400-406.
33. Sliutz G., Tempfer C., Winkler S., Kohlberger P., Reihthaller A., Kainz C. Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer. 72:(6):1995;1494-1497.
34. Hacker N.F. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer - therapeutic advance or surgical folly? Gynecol Oncol. 56:1995;325-371.